Dicitratobismuthate PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Acts through several local gastrointestinal mechanisms: forms a protective layer over ulcerated mucosa, increases mucus glycoprotein secretion, inhibits peptic activity and has activity against Helicobacter pylori. Its effects are not adequately described by a single molecular target.
Indications / reported uses
Treatment of gastric and duodenal ulcers
Part of combination regimens for Helicobacter pylori eradication, according to the current local product information and antimicrobial regimen
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Dicitratobismuthate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Dicitratobismuthate Permitted Daily Exposure (PDE) report (the Dicitratobismuthate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Dicitratobismuthate Occupational Exposure Limit (OEL) report (the Dicitratobismuthate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.